JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tahara, A.
Right arrow Articles by Tanaka, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tahara, A.
Right arrow Articles by Tanaka, A.

Vol. 282, Issue 1, 301-308, 1997

Pharmacological Profile of YM087, A Novel Potent Nonpeptide Vasopressin V1A and V2 Receptor Antagonist, in Vitro and in Vivo

Atsuo Tahara, Yuichi Tomura, Koh-Ichi Wada, Toshiyuki Kusayama, Junko Tsukada, Masahiro Takanashi, Takeyuki Yatsu, Wataru Uchida and Akihiro Tanaka

Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., 21 Miyukigaoka, Tsukuba, Ibaraki 305, Japan

The biochemical and pharmacological profile of YM087, 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)-carbonyl]-2-phenylbenzanilide monohydrochloride, a newly synthesized nonpeptide vasopressin (AVP) antagonist, was investigated in several in vitro and in vivo studies. YM087 showed high affinity for V1A receptors from rat liver and V2 receptors from rat kidney with Ki values of 0.48 and 3.04 nM, respectively. YM087 also inhibited [3H]oxytocin (OT) binding to rat uterus (OT receptors) plasma membranes with a Ki value of 44.4 nM, and at 100 µM did not affect the binding of [3H]AVP to anterior pituitary (V1B receptors) plasma membranes, which indicated that it had less affinity for these OT and V1B receptors. YM087 had no effect on cytosolic free calcium concentration ([Ca++]i) itself, but suppressed AVP-induced increase in [Ca++]i of cultured vascular smooth muscle cells at the same concentrations as the binding affinities. Furthermore, YM087 potently blocked AVP-induced cAMP production of cultured renal epithelium cells concentration dependently and had no agonistic activities. In in vivo studies, intravenous administration of YM087 inhibited the pressor response to exogenous AVP in pithed rats and produced an aquaretic effect in dehydrated conscious rats in a dose-dependent manner. These results demonstrate that YM087 is a potent and nonpeptide dual AVP V1A and V2 receptors antagonist and can be used in future studies to help clarify the physiological and pathophysiological roles of AVP.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 EndocrinologyHome page
K. Nakamura, Y. Fujiwara, R. Mizutani, A. Sanbe, N. Miyauchi, M. Hiroyama, J. Yamauchi, T. Yamashita, S. Nakamura, T. Mori, et al.
Effects of Vasopressin V1b Receptor Deficiency on Adrenocorticotropin Release from Anterior Pituitary Cells in Response to Oxytocin Stimulation
Endocrinology, October 1, 2008; 149(10): 4883 - 4891.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
B. Yangthara, A. Mills, V. Chatsudthipong, L. Tradtrantip, and A. S. Verkman
Small-Molecule Vasopressin-2 Receptor Antagonist Identified by a G-Protein Coupled Receptor "Pathway" Screen
Mol. Pharmacol., July 1, 2007; 72(1): 86 - 94.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. A. Munger
New agents for managing hyponatremia in hospitalized patients
Am. J. Health Syst. Pharm., February 1, 2007; 64(3): 253 - 265.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
M. Naitoh, J. Risvanis, L. C. Balding, C. I. Johnston, and L. M. Burrell
Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V1a and V2 receptor blockade and ACE inhibition
Cardiovasc Res, April 1, 2002; 54(1): 51 - 57.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
L. L. Wong and J. G. Verbalis
Vasopressin V2 receptor antagonists
Cardiovasc Res, August 15, 2001; 51(3): 391 - 402.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Yamamura, S. Nakamura, S. Itoh, T. Hirano, T. Onogawa, T. Yamashita, Y. Yamada, K. Tsujimae, M. Aoyama, K. Kotosai, et al.
OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats
J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 860 - 867.
[Abstract] [Full Text]

Home page
 Cardiovasc ResHome page
A. Tahara, Y. Tomura, K.-i. Wada, T. Kusayama, J. Tsukada, N. Ishii, T. Yatsu, W. Uchida, and A. Tanaka
Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte
Cardiovasc Res, April 1, 1998; 38(1): 198 - 205.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.